Latest from Incanthera

Incanthera says it's making great progress towards commercialisation of lead skin cancer asset

Incanthera's (LON:INC) Simon Ward and Tim McCarthy speak to Proactive following the release of its first set of results since listing earlier this year on the AQSE Growth Market.

CEO ward describes it as a pivotal year for the company and says they're now fully focused on further development of its skin cancer asset, Sol, which is making great progress towards commercialisation.